Poly-L-asparagine nanocapsules as anticancer drug delivery vehicles

被引:24
作者
Rivera-Rodriguez, G. R. [1 ,2 ]
Alonso, M. J. [1 ,2 ]
Torres, D. [2 ]
机构
[1] Univ Santiago de Compostela, Hlth Res Inst Santiago Compostela IDIS, Ctr Res Mol Med & Chron Dis CIMUS, Santiago De Compostela 15782, Spain
[2] Univ Santiago de Compostela, Sch Pharmacy, Dept Pharm & Pharmaceut Technol, Santiago De Compostela 15782, Spain
关键词
Polyasparagine; Nanocapsules; Nanocarriers; Anticancer drug delivery; Biopolymers; Nanomedicine; Targeted therapy; Docetaxel; NANOPARTICLES; DOCETAXEL; PHARMACOKINETICS; PACLITAXEL; LIPOSOMES; CARRIERS; TAXANES;
D O I
10.1016/j.ejpb.2013.08.001
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
This work presents for the first time the development of novel poly-L-asparagine (PASN) nanocapsules and the in vitro evaluation of their potential as anticancer drug delivery systems. The design of PASN nanocapsules was inspired by the well-known avidity of cancer cells for the amino acid L-asparagine together with the expected ability of this hydrophilic polymer to escape to the mononuclear phagocytic system. Besides, these nanocapsules have an oily reservoir, which enables the efficient encapsulation of lipophilic drugs. PASN nanocapsules were obtained by an emulsification-polymer layer deposition process, which involves using a cationic surfactant as a bridge for the interaction of PASN with the lipid core. PASN nanocapsules showed sizes of around 170-200 nm and negative zeta potential values (around -20 mV to -40 mV). The model anticancer drug docetaxel was efficiently encapsulated (around 75%) and retained within the nanocapsule's structure upon dilution in a simulated physiological medium. Moreover, these nanocapsules exhibited the ability to interact with the NCI-H460 human cancer cells and to enhance the cellular toxicity of the anticancer drug. All these features together with their adequate stability profile render these nanocapsules a new attractive platform for anticancer intracellular drug delivery. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:481 / 487
页数:7
相关论文
共 27 条
[1]
ALLAN JD, 1967, LANCET, V1, P682
[2]
Active targeting schemes for nanoparticle systems in cancer therapeutics [J].
Byrne, James D. ;
Betancourt, Tania ;
Brannon-Peppas, Lisa .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (15) :1615-1626
[3]
Development of positively charged colloidal drug carriers: Chitosan coated polyester nanocapsules and submicron-emulsions [J].
Calvo, P ;
RemunanLopez, C ;
VilaJato, JL ;
Alonso, MJ .
COLLOID AND POLYMER SCIENCE, 1997, 275 (01) :46-53
[4]
Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers [J].
Calvo, P ;
VilaJato, JL ;
Alonso, MJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 153 (01) :41-50
[5]
Forty-Year Journey of Angiogenesis Translational Research [J].
Cao, Yihai ;
Arbiser, Jack ;
D'Amato, Robert J. ;
D'Amore, Patricia A. ;
Ingber, Donald E. ;
Kerbel, Robert ;
Klagsbrun, Michael ;
Lim, Sharon ;
Moses, Marsha A. ;
Zetter, Bruce ;
Dvorak, Harold ;
Langer, Robert .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (114)
[6]
Chabner B., 2006, CANC CHEMOTHERAPY BI, P879
[7]
The taxanes: an update [J].
Crown, J ;
O'Leary, M .
LANCET, 2000, 355 (9210) :1176-1178
[8]
A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats [J].
Garcion, Emmanuel ;
Lamprecht, Alf ;
Heurtault, Beatrice ;
Paillard, Archibald ;
Aubert-Pouessel, Anne ;
Denizot, Benoit ;
Menei, Philippe ;
Benoit, Jean-Pierre .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (07) :1710-1722
[9]
A new potential nano-oncological therapy based on polyamino acid nanocapsules [J].
Gonzalo, Teresa ;
Lollo, Giovanna ;
Garcia-Fuentes, Marcos ;
Torres, Dolores ;
Correa, Juan ;
Riguera, Ricardo ;
Fernandez-Megia, Eduardo ;
Calvo, Pilar ;
Aviles, Pablo ;
Jose Guillen, Maria ;
Jose Alonso, Maria .
JOURNAL OF CONTROLLED RELEASE, 2013, 169 (1-2) :10-16
[10]
Hervella P, 2011, NANOCOMPOSITE PARTICLES FOR BIO-APPLICATIONS: MATERIALS AND BIO-INTERFACES, P45